The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FIRST-NEC (GFPC 01-2022): A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab with etoposide and platinum as first line treatment in patients with advanced large-cell neuroendocrine lung carcinomas (LCNECs).
 
Dominique Arpin
No Relationships to Disclose
 
Julien Gautier
No Relationships to Disclose
 
Audrey Mansuet-Lupo
No Relationships to Disclose
 
Romain Corre
Honoraria - AstraZeneca/MedImmune; Bristol Myers Squibb; MSD Oncology
Consulting or Advisory Role - Amgen; AstraZeneca; Lilly; MSD Oncology; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Takeda
 
Aymeric De Monfort
No Relationships to Disclose
 
Sylvie Chabaud
No Relationships to Disclose
 
Chantal Decroisette Phan Van Ho
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Janssen Cilag; MSD Oncology; Novocure; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - Roche; Takeda
 
Sébastien Couraud
Expert Testimony - Amgen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Health Event; Novartis; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Pfizer; Roche
 
Marie Wislez
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Inhatarget; Janssen Oncology; Lilly; Merck KGaA; Merck KGaA; MSD Oncology; Novartis; Novocure; Pfizer; Roche; Sanofi; Takeda; Transgene
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Lilly; Regeneron
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; MSD Oncology; Pfizer; Regeneron; Takeda
 
Simonneau Yannick
Travel, Accommodations, Expenses - MSD
 
Solene Chaleat
No Relationships to Disclose
 
Charles Ricordel
Consulting or Advisory Role - BMS; MSD; Takeda
 
Anne Claire Toffart
Consulting or Advisory Role - Astra Zeneca, BMS, Janssen, MSD, Pfizer, Roche, Sanofi, Takeda
Speakers' Bureau - Astra Zeneca, BMS, Janssen, MSD, Pfizer, Roche, Sanofi, Takeda
Travel, Accommodations, Expenses - Pfizer, Roche, Takeda
 
Didier Debieuvre
Honoraria - Amgen; AstraZeneca; BMS France; Janssen; MSD; Pfizer; Roche; Sanofi/Regeneron; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; BMS France; Janssen; MSD Oncology; Pfizer; Sanofi/Aventis
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BMS france (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Janssen Oncology; MSD Oncology; PharmaMar; Takeda
 
Ivana Sondarjee
No Relationships to Disclose
 
Jean-Bernard Auliac
No Relationships to Disclose
 
Diane Damotte
Research Funding - AstraZeneca/MedImmune
 
Laurent Greillier
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Novocure; Pfizer; Regeneron; Roche; Sanofi; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Novocure; Roche; Takeda
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BMS; MSD; Pfizer; Roche
 
David Pérol
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Brenus Pharma; Bristol Myers Squibb Foundation; DAIICHI SANKYO; Gilead Sciences; IPSEN; Janssen; Lilly; MSD; Novartis; Pfizer; TAKEDA
Travel, Accommodations, Expenses - Novartis; Roche
 
Luc Odier
Honoraria - Amgen
Consulting or Advisory Role - Janssen; Takeda
Travel, Accommodations, Expenses - ASDIA; Pfizer